Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OmniAb, Inc.OABI · Entity 5294 | Director | June 23, 2023 | June 27, 2023 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | See Remarks | January 04, 2018 | January 08, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OmniAb, Inc.
Report date June 23, 2023 · Filed June 27, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 20,000 |
Reported balance
After 2023-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-23 · Grant · Acquired 20,000 · Balance 20,000 F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81 · Expires 2033-06-23 | Direct | 40,000 |
Reported balance
After 2023-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-23 · Grant · Acquired 40,000 · Balance 40,000 F2: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the annual meeting of the Company's stockholders next following the grant date and (B) on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in full on the earlier of (A) the date of the next annual meeting of the Company's stockholders following the grant date and (B) the first anniversary of the date of grant.
F2: Each Stock Option shall vest and become exercisable in full on the earlier of (A) the date of the annual meeting of the Company's stockholders next following the grant date and (B) on the first anniversary of the date of grant.
OncoMed Pharmaceuticals Inc
Report date January 04, 2018 · Filed January 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.98 · Expires 2028-01-03 | Direct | 100,000 |
Reported balance
After 2018-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-04 · Grant · Acquired 100,000 · Balance 100,000 F1: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,820 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 1,004 · Balance 28,820 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-06-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 4,340 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders following the grant date or (ii) on June 10, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2017 Filed Jan 5, 2017 19:08 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001140361-17-000852 · doc1.xml · derivative · entry 1 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-01-02 F1 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 09, 2016 Filed Oct 11, 2016 21:41 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-082538 · doc1.xml · nonDerivative · entry 1 Patel Sunil · CIK 0001503062 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,338 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 27,500 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.